Trials / Terminated
TerminatedNCT03499678
Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
Clinical Trials on Detection of Lung Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC and T Cells
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 81 (actual)
- Sponsor
- HKGepitherapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A central challenge in the fight against lung cancers is how to detect disease in a noninvasive manner before it is detectable by imaging methods. Although inroads have been made with more sensitive imaging techniques for earlier detection of breast and lung cancers, these techniques are limited by the size of lesion that could be detected. Alternatively, several blood proteomic biomarkers have been proposed but none offer as of yet sufficient predictive power. Consequently, effective non-invasive tools as prognostic indicators and biomarkers of lung cancer is urgently needed. The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC and circulated tumor DNA in lung cancer patients.
Conditions
Timeline
- Start date
- 2018-07-01
- Primary completion
- 2019-07-19
- Completion
- 2019-07-19
- First posted
- 2018-04-17
- Last updated
- 2023-12-22
Locations
1 site across 1 country: Kazakhstan
Source: ClinicalTrials.gov record NCT03499678. Inclusion in this directory is not an endorsement.